Biomedical Advanced Research and Development Authority (BARDA)

Today, our partner CARB-X published their annual report that highlights continued efforts accelerating early-stage antibacterial candidates into clinical development to help fill strategic gaps in the antimicrobial resistance (AMR) medical countermeasures pipeline. The report showcases project milestones, new funding commitments, upcoming funding rounds, and Portfolio Acceleration Tools.    As a founding funder of the CARB-X global accelerator, BARDA is dedicated to advancing novel and innovative medical countermeasures to help combat the threat of drug-resistant infections and increase the USG’s preparedness posture.     To read more about the progress achieved by CARB-X developers over the past year, visit https://lnkd.in/e27JjCn Learn more about our partnership with CARB-X and how we are working together to address AMR: https://lnkd.in/dSW3vwvP 

This National Minority Health Month, we’re highlighting the necessity for diversity in clinical trials. While approximately 40% of the U.S. population is made up of racial and ethnic minorities, they are often underrepresented in clinical trials. A key component of our Strategic Plan is to ensure underrepresented populations are included in clinical trials. One of the ways we’re enabling increased health equity and diversity in clinical trials is through our partnership with company like Acclinate, one of the BARDA and Johnson & Johnson Innovation – JLABS Blue Knight program portfolio companies. Acclinate is a digital health company working to improve health equity through predictive analytics technology and community engagement. They specialize in accessing and engaging communities of color so individuals can make informed health decisions and learn about clinical trial participation. Through Acclinate’s omnichannel platform, NOWINCLUDED, they provide education, resources, and research opportunities to community members.

Happy Earth Day! Celebrated annually on April 22, Earth Day demonstrates the collective power people have to make a difference and show support for our planet!

This National Minority Health Month, we’re highlighting ways in which we can help advance health preparedness in communities and nationwide. Our Accelerator Network partners UEL and Gener8tor connect socially and economically disadvantaged startups that have promising innovative technologies to educational resources and stakeholders that can accelerate business and product development. In addition to supporting startup founders, the BARDA Accelerator Network partners run programming to support underrepresented founders, including the gBETA MedTech Black Founder Accelerator program. Over two cohorts supported by BARDA, the gBETA MedTech Black Founder Accelerator program has supported 10 companies, creating 45 jobs and raising $404k. To learn more and contact us, visit: https://ow.ly/gEHE50Rj3rJ

Are you currently developing a medical countermeasure, technology platform, or manufacturing capability and think it might align with our mission space? We want to hear from you – submit a TechWatch today! Benefits of TechWatch meetings include: ✔️ Receive feedback from USG experts ✔️ Hear strategies for addressing technical and regulatory challenges ✔️ Get insight on how your solution could fit within the government ✔️ Better prepare you for a formal proposal submission Request a meeting today and be part of One Million Acts of Science. To learn more and request a TechWatch meeting, visit: https://ow.ly/zkxe50RhfQ4

DEADLINE UPDATED: EZ-BAA AOI #25: FASTx closing date for abstract submissions is now May 31, 2024. We’re still seeking proposals to support early-stage development of therapeutic platforms. Interested parties can submit requests for a pre-proposal market research call to FASTx@hhs.gov. Learn more: https://ow.ly/IemQ50QXK3W

Have you registered yet for the Blue Knight Symposium we’re hosting with Johnson & Johnson Innovation – JLABS? Join us on June 2 in San Diego to connect with global preparedness leaders and next generation innovators. Register today: https://jji.jnj/3woPmf6

We are encouraging the next generation of the STEM workforce through our SPRINT program, which partners with local schools in D.C., Maryland, and Virginia to engage students on scientific topics encompassed in BARDA’s mission, encourages students to consider a career in STEM and public service, and aims to generate excitement about BARDA's work in the biomedical and health security fields. Through SPRINT, students have access to educational programming, career advice, internships, mentorships and special events focused on STEM and civil service. This Citizen Science Month, learn how you can get involved and be part of One Million Acts of Science: https://ow.ly/Quhs50Rhf9b

BARDA joined industry partner Jubilant HollisterStier CMO for a ribbon cutting ceremony and a tour of their high-speed, commercial fill-finish line facility in Spokane, Washington. Filling and finishing vials are the last two steps in the manufacturing process for vaccines and therapeutics. During a pandemic or infectious disease outbreak, it is critical to ensure that the nation has enough domestic capacity to complete those final steps and make vaccines and therapeutics available. This project with Jubilant HollisterStier aims to enable faster production of vaccines in the U.S. when needed and to help bolster preparedness ahead of the next public health emergency. Learn more about how we’re making critical investments to foster and expand domestic pharmaceutical manufacturing: https://ow.ly/zvvY50Rfvsk

Emergency Medical Personnel: Did you know that you can remove 99% of chemical contamination by having the patient disrobe and blot their skin with dry absorbent material? Learn more about PRISM, an evidence-based guidance for human chemical decontamination, developed in collaboration with emergency responders: https://ow.ly/3kmw50RfpLC BARDA’s Chemical MCMs Program uses a threat-agnostic approach to develop multipurpose treatments and use commonly available drugs to treat injuries caused by chemicals. For more about the program, visit: https://ow.ly/GmpB50RfpLB